UBS Group’s Medline Inc MDLN Stock Holding History

UBS Group’s Portfolio MDLN Stock Details MDLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$142M	Buy	3,191,661 +1,889,113	+145%	+$83.4M	0.02%	799
2025 Q4	$54.7M	Buy	+1,302,548	New	+$55M	0.01%	1522

Other funds holding MDLN

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

HFCIX

H&F Corporate Investors X San Francisco, California $3.85B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

UBS Group's MDLN Position: Q1 2026 in Review

UBS Group increased its Medline Inc (MDLN) stake by 145% in Q1 2026, buying an estimated $83.4M and bringing the position to 3,191,661 shares worth $142M. The position accounts for 0.02% of the portfolio, ranked #799.

UBS Group first reported a position in MDLN in Q4 2025 and has held it in 2 quarters since. 314 funds tracked by Wall St. Rank hold MDLN as of Q1 2026.

UBS Group held 3,191,661 shares of Medline Inc worth $142M as of Q1 2026.
UBS Group bought 1,889,113 Medline Inc shares in Q1 2026, an estimated $83.4M.
Medline Inc made up 0.02% of UBS Group's portfolio in Q1 2026, its #799 holding.
UBS Group first reported a position in Medline Inc in Q4 2025 and has held it in 2 quarters since.
314 funds tracked by Wall St. Rank held Medline Inc as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.